Presence of CD34 + in Megakaryocytes in Association With p53 Expression Predicts Unfavorable Prognosis in Low-risk Myelodysplastic Syndrome Patients

• Published in: In vivo (Athens) Vol. 33; no. 1; pp. 277 - 280
• Main Authors: Duarte, Fernando Barroso, DE Jesus Dos Santos, Talyta Ellen, Barbosa, Maritza Cavalcante, Moura, Anna Thawanny Gadelha, DE Vasconcelos, João Paulo Leitão, Rocha-Filho, Francisco Dário, Coutinho, Diego F, Zalcberg, Ilana, Vasconcelos, Paulo R L, Garcia, Yhasmine Delles Oliverira, Lemes, Romélia Pinheiro Gonçalves
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01-01-2019
• Subjects: low risk; p53 protein expression; prognosis; Myelodysplastic syndromes; CD34 on megakaryocytes
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.11472

Although risk stratification using the Prognostic Scores Systems (IPSS, WPSS and IPSS-R) incorporate key information about prognosis of patients with Myelodysplastic syndromes (MDS), patients classified as low-risk may evolve rapidly and aggressively, despite a "favorable" prognostic stratification. The aim of this study was to identify biomarkers for predicting prognosis, and for better stratification and management of these patients.
Expression of CD34 and p53 in megakaryocytes was examined by immunohistochemistry in 71 MDS patients classified as low-risk.
CD34 staining in megakaryocytes was associated with p53 expression (p=0.0166). CD34 and p53 expression were associated to worse overall survival in patients (p=0.0281).
The presence of CD34 in megakaryocytes is associated with p53 expression and an adverse prognosis for MDS patients.